Methylnaltrexone: Phase II start

Next quarter, PGNX will begin a U.S. Phase II trial in about 260 OIC patients rehabilitating from an orthopedic surgical procedure to compare subcutaneous methylnaltrexone vs. placebo for 7 days or un...